Modality
Degrader
MOA
USP1i
Target
EGFR
Pathway
Epigenetic
CTCLOCDWM
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Apr 2031
Phase 2Current
NCT05418152
2,167 pts·OCD
2025-04→2031-04·Terminated
NCT06319060
2,312 pts·CTCL
2021-08→2025-09·Recruiting
4,479 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-097mo agoPh2 Data· CTCL
2031-04-245.1y awayPh2 Data· OCD
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Recruit…
P2
Termina…
Catalysts
Ph2 Data
2025-09-09 · 7mo ago
CTCL
Ph2 Data
2031-04-24 · 5.1y away
OCD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05418152 | Phase 2 | OCD | Terminated | 2167 | CR |
| NCT06319060 | Phase 2 | CTCL | Recruiting | 2312 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR |